[A therapeutic trial of mazindol versus placebo in Duchenne muscular dystrophy. A one-year follow-up study of 14 children].

Abstract

A simple-blind therapeutic trial of mazindol (2 mg/d) versus placebo in 14 boys with Duchenne muscular dystrophy, 5 to 13 years old, for 12 months was conducted in order to analyse the efficacy of this drug on the natural history of the disease. Evaluation of muscle strength by manual testing, motor ability by functional testing and timed tests, weight, height, serum CK and pulmonary function were performed every two months. The differences in evolution between groups were significant only for weight and height. However comparison of muscle strength and of vital capacity expressed as percent of predicted at the beginning and at the end of the study suggested a beneficial trend in the mazindol-treated group.

• Authors: C Desnuelle, G Serratrice, V K N'guyen, C Richelme, N Pinsard
• Journal: Archives francaises de pediatrie (Arch Fr Pediatr) Vol. 46 Issue 10 Pg. 759-65 (Dec 1989) ISSN: 0003-9764 [Print] France
• Vernacular Title: Essai thérapeutique du mazindol contre placebo dans la dystrophie musculaire de Duchenne. Suivi de l'évolution pendant 1 an chez 14 enfants.
• PMID: 2697199 (Publication Type: Clinical Trial, Controlled Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial)

Chemical References

• Indoles
• Placebos
• Mazindol
• Creatine Kinase

Topics

• Adolescent
• Child
• Child, Preschool
• Clinical Trials as Topic
• Creatine Kinase (blood)
• Drug Evaluation
• Follow-Up Studies
• Humans
• Indoles (pharmacology)
• Male
• Mazindol (pharmacology)
• Muscle Tonus (drug effects)
• Muscular Dystrophies (drug therapy)
• Placebos
• Respiratory Function Tests